Search Results

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX’s CAR-T cell therapy in patients with kappa-type myeloma.

Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER about his thoughts on the future of cell and gene therapies.

In this short teaser, BioSpace’s Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder of the Emily Whitehead Foundation about anticipated discussions at the upcoming GenScript Biotech Forum.

Peter MacCallum Cancer Centre, world leading cancer research, education and treatment center and Isotopia Molecular Imaging Limited (Isotopia), a global supplier of radioisotopes for targeted therapies, today announced they have signed a clinical research and supply agreement for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161).,

BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced a research collaboration agreement with the Peter MacCallum Cancer Centre (Peter Mac), a world leading research, education, and treatment center in Melbourne, Australia.

Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication,” Jefferies analyst Peter Welford wrote in a note to investors.